target
""
3PLpro
Active at viral post-entry stage (unknown target)
Adaptor associated kinase 1
Alpha-glucosidase inhibitor active against Omicron
An anticoagulant and antiviral drug being repurposed for COVID-19 treatment
Anti-inflammatory drug repurposed for COVID-19 treatment
Anticancer drug being re-purposed for COVID-19
Anticancer drug being repurposed for COVID-19 treatment
Antidiabetic drug being repurposed for COVID-19 treatment
Antidote of SARS-CoV-2 VOC-202012/01 strain
Antifungal drug being repuposed for COVID-19 treatment
Antioxidant and anti-inflammatory agent being repurposed for COVID-19 treatment
Approved anticoagulant drug
Approved drug for covid-19 drug
Approved for COVID-19 treatment
Authorized by FDA as emergency SARS-CoV-2 drug
Blocks viral RNA genome synthesis
COX-2
Caspase blocker
Cathepsin L
Clinical trial candidate
Could be used for COVID-19 treatment
DPP4
Drug shows synergistic cytopathic inhibition in combination with Ritonavir
E protein
FDA approved drug for covid-19 drug
FDA approved drug for covid-19 treatment
Furin
HDAC inhibitor
"Inhibitor of a translation initiation factor, PB28"
Inhibitor of melanin synthesis being repurposed for COVID-19 treatment
Inhibits viral entry (unknown target)
Inhibits viral multiplication (protease inhibitor)
Inhibits viral proliferation (unknown target)
Inhibits viral replication
Inhibits viral replication (protease inhibitor)
Inhibits viral replication (unknown target)
Inknown target
Inosine monophosphate dehydrogenase
Intracellular viral inhibition
Investigated in preclinical studies
Ion exchange function of Na+/K+
Kinase inhibitor being repurposed for COVID-19 treatment
LTA4 inhibitor and SEH inhibitor that suppresses lung inflammation
Lopinavir-ritonavir combination being repurposed drug for COVID-19 treatment
Mpro
Mtase
N protein
NPC-1 protein
NS3 helicase
NS5B
NSP15
NSP16
NSP3
NSP7
Nucleocapsid phosphoprotein
OAT3
Other targets
PLP2
PLpro
Preclinical candidate
RdRp
Reduce the plaque formation of SARS-CoV-2
Repurposed drug for COVID-19
Rheumatoid arthritis and investigated in preclinical studies against COVID-19
S protein
S-cysteinase
SEH inhibitor that suppresses lung inflammation
"SEH inhibitor that supresses lung inflammation, hence could be used for COVID-19 treatment"
Serine protease inhibitor
Spike/ACE2
TMPRSS2
TMPSSR2
TPC-2 protein
Targets multiple kinases
Underwent clinical trials for COVID-19 treatment
Unknown target
Viral entry inhibitor
Viral entry inhibitor (phosphoinositide 3-kinases /AKT/AP2M1 pathway)
Viral entry inhibitor (unknown target)
Viral growth inhibitor (unknown target)
approved anti-epileptic drug
being repurposed as potential agents to treat SARS-CoV-2 infection
catepsin L
cathepsin L
eEF1A protease
eIF4E
fusion inhibitor
helicase
host catepsin L
orf6 protein
polymerase inhibitor
protease inhibitor
repurposed for COVID-19 treatment
up-regulation of host IRE1 ribonuclease endoplasmic reticulum (ER) stress response and interferon signaling pathways
viral polymerase
